|
1) Sakuma M, Sugimura K, Nakamura M, et al. Unusual pulmonary embolism –septic pulmonary embolism and amniotic fluid embolism–. Circ J. 2007; 71: 772-5
|
|
|
|
2) Sakuma M, Nakamura M, Takahashi T, et al. Pulmonary embolism is an important cause of death in young adults. Circ J. 2007; 71: 1765-70
|
|
|
|
|
|
3) Kobayashi T, Nakabayashi M, Ishikawa M, et al. Pulmonary thromboembolism in obstetrics and gynecology increased by 6. 5 fold over the last decade in Japan. Circ J. 2008; 72: 753-6
|
|
|
|
|
|
4) 小林隆夫, 中林正雄, 石川睦男, 他. 産婦人科血栓症調査結果 2001-2005. 日産婦新生児血会誌. 2008; 18: S3-S4
|
|
|
|
|
|
5) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会, 編. In: 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン. 東京: メディカルフロントインターナショナルリミテッド; 2004. p. 1-96
|
|
|
|
|
|
6) Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756-64
|
|
|
|
|
|
7) Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001; 119 (1 Suppl): 132S-175S
|
|
|
|
|
|
8) Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol. 2001; 20: 1-37
|
|
|
|
|
|
9) Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004; 126 (3 Suppl): 338S-400S
|
|
|
|
|
|
10) Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133 (6 Suppl): 381S-453S
|
|
|
|
|
|
11) Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006; 25: 101-61
|
|
|
|
|
|
12) Sakuma M, Fukui S, Nakamura M, et al. Cancer and pulmonary embolism –thrombotic embolism, tumor embolism, and tumor invasion into a large vein–. Circ J. 2006; 70: 744-9
|
|
|
|
|
|
13) Sakon M, Maehara Y, Yoshikawa H, et al. Incidence of venous thromboembolism following major abdominal surgery: a multi-center, prospective epidemiological study in Japan. J Thromb Haemost. 2006; 4: 581-6
|
|
|
|
|
|
14) Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25: 5490-505
|
|
|
|
|
|
15) Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann Surg. 2006; 243: 89-95
|
|
|
|
|
|
16) Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Int Orthop. 2008; 32: 443-51
|
|
|
|
|
|
17) Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133: 844-86
|
|
|
|
|
|
18) Hiipala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replasement of major blood loss with plasma-poor red cell concentrates. Anesth Analg. 1995; 81: 360-5
|
|
|
|
|
|
19) B-Lynch C, Coker A, Lawal AH, et al. The B-Lynch surgical technique for the control of massive postpartum haemorrhage: an alternative to hysterectomy？ Five cases reported. Br J Obstet Gynaecol. 1997; 104: 372-5
|
|
|
|
|
|
20) Alfirevic Z, Elbourne D, Pavord S, et al. Use of recombinant activated factor VII in primary postpartum hemorrhage. The northern European registry 2000-2004. Obstet Gynecol. 2007; 110: 1270-8
|
|
|
|
|
|
21) Welsh A, McLintock C, Gatt S, et al. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust NZJ Obstet Gynaecol. 2008; 48: 12-6
|
|
|
|
|
|
22) Nohira T, Osakabe Y, Suda S, et al. Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage. J Obstet Gynaecol Res. 2008; 34(4 Pt 2): 623-30
|
|
|
|
|
|
23) Franchini M, Manzato F, Salvagno GL, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagul Fibrinolysis. 2007; 18: 589-93
|
|
|
|
|
|
24) Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. Br J Obstet Gynaecol. 2007; 114: 8-15
|
|
|
|
|
|
25) Karalapillai D, Popham P. Recombinant factor VIIa in massive postpartum haemorrhage. Int J Obstet Anesth. 2007; 16: 299-300
|
|
|
|
|
|
26) 小林隆夫, 中林正雄, 吉岡 章. 産科大量出血例に対する遺伝子組換え活性型血液凝固第VIII因子製剤の有用性. 日本血栓止血学会誌. 2009; 20: 154
|
|
|
|
|
|
27) Franchini M, Franchi M, Bergamini V, et al. A Critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost. 2008; 34: 104-12
|
|
|
|
|
|
28) Vincent JL, Rossaint R, Riou B, et al. Recommendations on the use of recombinant activated factor VIII as an adjunctive treatment for massive bleeding- a European perspective. Crit Care. 2006; 10: R120
|
|
|
|
|
|
29) van Veen EJ, Monteban-Kooistra WE, Meertens JH, et al. Recombinant human activated factor VII in postpartum hemorrhagic shock: the dark side. Intensive Care Med. 2007 Aug 1 (Correspondence)
|
|
|
|
|